March 30, 2026
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
March 4, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 19, 2026
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
February 9, 2026
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
February 4, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2026
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
January 12, 2026
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
January 9, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 8, 2026
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
January 6, 2026
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
Displaying 1 - 10 of 11